semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Abdominal Pain Inflammatory Bowel Diseases Irritable Bowel Syndrome General Aged 18 and over Sufficient command of written and spoken English IBD in remission Proof of diagnosis of IBD (Crohn's disease or ulcerative colitis) for more than 6 months Clear indicators of remission: on faecal calprotectin (≤200 µg/g) or measurements of C-reactive protein (CRP; ≤10 mg/dl) within the last 3 months or as part of recruitment No previous episodes of acute or sub-acute obstruction IBS Current diagnosis of IBS measured with Rome IV No serious other bowel diseases  Major abdominal surgery in the last 6 months, or 3 or more previous major abdominal surgeries Pregnancy or childbirth in the last 6 months Any other diagnosed medical condition that may explain abdominal pain, including but not limited to known gynaecological conditions such as endometriosis and known post-surgical adhesions Any diagnosed co-morbid medical conditions associated with known neuropathy, such as diabetic neuropathy, renal neuropathy, multiple sclerosis Use of opioids in the last week Use of anti-depressants used as pain medication in the last month
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 6.0-11.0,  Traveler's Diarrhea Diagnosis of acute bacterial diarrhea defined as at least 3 unformed stools within the 24 hours preceding randomization, with a duration of illness ≤72 h. The bacterial origin of diarrhea will be confirmed "a posteriori" by stool microbiology sampling at the time of screening Presence of one or more signs or symptoms of enteric infection, including nausea, vomiting, abdominal cramps or pain, tenesmus, urgency History of recent travel from an industrialized country to a developing region with a known high incidence of travelers' diarrhea Male or female 6-11 years of age, providing an unformed pre-treatment stool The parent or legally acceptable representative must provide informed consent for the subject. The Subject must also provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing  Fever (>100.4ºF or 38ºC), or presence of signs and symptoms of systemic infection Known or suspected infection with non-bacterial pathogen Symptoms of acute diarrhea of >72 hours duration Presence of grossly bloody stool Moderate to severe dehydration History of inflammatory bowel disease (IBD) Abdominal ileus Severe dehydration Greater than two doses of an antidiarrheal medication within 24 hours before randomization, or any symptomatic therapy within 2 hours before enrolment Receiving antimicrobial drug with expected activity against enteric bacterial pathogens within the week prior to enrolment
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Participants must be females of post-menopausal status with HR+, HER2 breast cancer that has spread to internal organs Participants must have had at least one endocrine therapy Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study  Participants must not have breast cancer that has spread to the brain if untreated and with symptoms Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy Participants must not have certain active infections including HIV or hepatitis Participants must not be pregnant or breastfeeding Participants must not have certain types of cancers or certain previous cancer treatments Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pulmonary Embolism acute pulmonary embolism catheter-directed embolectomy  appropriate data not available
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection (CDI) ≥18 years of age 2. Currently an inpatient at UPMC Presbyterian 3. Diagnosed with an CDI 4. Being treated with Fidaxomicin  not meeting entry
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Patients who have granted the IC and who are going to comply with the study visits and procedures according to their life expectations Patient ≥ 18 years of age Having a first episode of DCI and presenting an estimated recurrence risk greater than 35%  Patients <18 years old Pregnant or lactating women Women of childbearing age who are not willing to use an appropriate contraceptive method (such as oral contraceptives, intrauterine device or contraceptive barrier method along with spermicide or surgical sterilization) during the study Life expectancy less than 6 months Impossibility or serious difficulties of clinical follow-up Any digestive disease that, at the discretion of the researcher, makes it difficult to assess the response due to impaired bowel habits Immunoglobulin treatment in the last 3 months Previous treatment with Bezlotoxumab Treatment with an experimental drug in the previous 30 days or participating or planning to participate in any other clinical trial with an experimental drug during the 12-week trial period Anti
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Secondary Peritonitis > 18 years in Automated Peritoneal Dialysis Patients in the Hospital General 1, 10 and sub-zone 4 of Colima Patients with diagnosis of peritonitis (abdominal pain, fever, vomiting, nausea, turbid fluid, cytologic with leukocytes >100 cells/mm3, polymorphonuclear >50%) Functional catheter Signed informed consent of acceptance to participate in the study  Patients allergic to vancomicyn Patients allergic to ceftazidime Patients with Intestinal perforation Patients with abdominal cavity classified as unfit to PD
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postpartum Women women aged between 18-45 years old in the 6th-8th week postpartum both vaginal or caesarean delivery both primiparous or multiparous women  previous abdominal or pelvic surgery reasons to suspect metabolic, neurological or neuromuscular disease multiple birth delivery
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Community-acquired Pneumonia Hospitalized with community-acquired pneumonia; defined as new pulmonary infiltrate on chest X-ray and at least one symptom compatible with pneumonia (cough, fever, dyspnoea and/or chest pain) Initiation of antibiotics within 12 hours of the time of the chest X-ray with an infiltrate Age ≥ 18 years Afebrile (temperature ≤ 37.8 °C) for 48 hours at randomization Clinically stable at randomization (systolic blood pressure ≥ 90 mm Hg, heart rate ≤ 100/min., respiratory rate ≤ 24/min., peripheral oxygen saturation ≥ 90%)  Immunosuppression (HIV-positive, neutropenia, corticosteroid treatment (≥10 mg/day of prednisone or the equivalent for >30 days), chemotherapy, immunosuppressive agents, immunosuppressed after solid organ transplantation, asplenia) Hospitalization during the previous 14 days Antibiotic treatment (>2 days) within the past 30 days Uncommon cause requiring longer duration of antimicrobial therapy (Pseudomonas aeruginosa, Staphylococcus aureus, Mycobacterium spp., fungi) Extrapulmonary infection (e.g. endocarditis, meningitis, or abscess) Pleural empyema or lung abscess Pleural effusion requiring drainage tube Intensive care unit (ICU) admittance Pregnancy and breastfeeding
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Clostridium Difficile Infection Recurring CDI after three episodes of mild to moderate C Diff infections and failure to respond to appropriate antimicrobial treatment of six to eight weeks Metronidazole Vancomycin At least two episodes of severe C diff infection that have required hospitalization and significant morbidity within one year Severe C Diff infection requiring hospitalization and non responsive to maximal medication therapy  advanced Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS) cirrhosis of the liver recent bone marrow transplants medication suppressed immune systems (allowed per physician discretion if benefit outweighs risk) pregnancy Toxic megacolon or ileus present
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Inflammatory Bowel Diseases All patients with IBD admitted at EL-Raghy Assiut university hospital in the period of first of October 2019 to the end of September 2020 The diagnosis of DM is confirmed by high random blood glucose level more than 200mg/dl three times per day or high HbA1c more than 6.5%. The diagnosis of IBD is confirmed by colonic biopsy results after colonoscopy  Patients didn't do colonoscopy or didn't get biopsy or with normal colonoscopy and biopsy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Clostridium Difficile Infection (CDI) In order to be eligible to participate in this study, an individual must meet all of the following Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study Male or female, aged 18 to 89 In good general health as evidenced by medical history or Diagnosed with specific condition/disease or Exhibits specific clinical signs or symptoms or physical/oral examination findings Participant has a diagnosis of CDI defined as (i) presence of diarrhea with 4 or more unformed stools within 24 hours and (ii) positive test for toxigenic C. difficile from stools collected within 7 days Participants received < 24 h of SOC therapy for CDI Participants presented with primary CDI episode or first recurrence of CDI Participants comply with the and willing to participate in the study including the 8 week post treatment follow up period White Blood Cell absolute neutrophil count <15 x 109/L  An individual who meets any of the following will be excluded from participation in this study known allergic reactions to chicken egg components Female of child bearing potential and not receiving contraception; pregnant or lactating persons severe CDI defined as >10 unformed bowel movements (UBMs)/24 h period, fever >38.5 o C, White Blood Cell count > 15 x 109/L, abdominal pain and tenderness on physical examination, toxic megacolon, ileus, nausea, vomiting receipt of > 24 h of SOC treatment of CDI, or fecal microbial transplant (FMT) prior to enrollment treatment with another investigational drug or other intervention within 30 days prior to enrollment including intravenous immunoglobulin (IVIG) or monoclonal intravenous (IV) antibody received vaccine for C. difficile concurrent use of probiotics of any type during treatment and follow up unable to discontinue use of opiates for diarrhea control co-infection with another gastrointestinal (GI) pathogen
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Abdominal Pain Should be able to give informed consent for the study Has Enterra GES device in place for at least 2 months Continue to have moderate to severe abdominal pain on at least one pain questionnaire or >5 score (on a scale of 0-10 for pain) on the VAS questionnaire for at least 2 months Abdominal pain should be either persistent; for example, daily for at least >1 hour, be chronic for >2 months, and refractory to original Enterra GES settings  Unable to provide informed consent Pregnancy Any other active health problems that would render patient unable to complete the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Clostridium Difficile Infection All consecutive adult patients (inpatients and outpatients) who have a treated first episode or first recurrence of CDI CDI will be defined by a positive PCR for toxin gene and/or detection of toxin by EIA or CCA along with three or more episodes of diarrhea within 24 hours Patients with a positive test with less than three bowel movements may be included if they initially presented with ileus or if they had pseudomembranous colitis visualized on colonoscopy  Clinical: 1. Toxic megacolon at presentation not resolved by day 10 2. For the current episode of CDI: use of fidaxomicin, fecal microbiota transplant or intravenous immunoglobulins 3. Previous or current colectomy 4. Severe allergy/intolerance to oral vancomycin 5. Patient is expected to die within 3 months from another disease or is expected to be admitted to a palliative care unit 6. Failure to achieve clinical cure (as above) by day 10 7. More than 2 lifetime episodes of C. difficile Administrative: 1. Expected transfer to a palliative care unit or non-study hospital; 2. No provincial health insurance 3. Previously enrolled 4. No reliable means of outpatient contact 5. Incompetent without healthcare proxy 6. Patient stated inability to come to follow up appointments
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Adult patients (>18 years old). 2. Colon cancer patients ???? who will receive adjuvant 6& 6 for 6 cycles. 3. ECOG performance status 0-2 4. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin <1.5 mg/dl), renal function (creatinine <1.5 mg/dl)  Patients who have Clinical GIT mucositis or Periodontal disease. 2. Patients with other primary malignancy. 3. Patients receiving mTOR inhibitors (eg, rapamycin, everolimus, and temsirolimus), EGFR inhibitors (eg, bevacizumab and erlotinib) and tyrosine-kinase inhibitors (eg, sorafenib and sunitinib). 4. Hypersensitivity to Atorvastatin. 6-Pregnant and lactating women. 7 Patients treated with ATV for any other indication. 8- Patient who already have a mucositis
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hospital-acquired Pneumonia Any patient hospitalized for ≥ 48 hours aged 18 years or older not mechanically-ventilated at with of pneumonia Dated and signed inform consent Affiliation with a social security scheme of pneumonia New lung infiltrate on a chest-x ray plus Evidence that the infiltrate is of an infectious origin, i.e. new onset of fever (> 38.5°C) and/or purulent sputum and/or leukocytosis and/or decline in oxygenation  • Congenital or acquired immunodeficiency: neutropenia (<1 leucocyte/mL or < 0.5 neutrophil/mL), HIV infection, allograft/autograft of hematopoietic stem cells, solid organ transplantation, uptake of immunosuppressive drugs, uptake of corticosteroids >10 mg/day equivalent prednisone for a duration ≥15 days before screening Patients with chronic bronchitis structural changes: very severe COPD (Global initiative for chronic Obstructive Lung Disease GOLD 4), tracheostomy, bronchiectasis, cystic fibrosis Radiological evidence of thoracic empyema, pulmonary abcess Moribund patient or death expected from underlying disease during the current admission